Revenue, 2025

USD 520 Million

Forecast, 2035

USD 1112.29 Million

CAGR, 2026-2035

7.9%

Report Coverage

Global

Activated Clotting Time Testing Market Trends for 2026

The global activated clotting time testing market size was estimated at USD 520 million in 2025 and is predicted to increase from USD 561.08 million in 2026 to approximately USD 1112.29 million by 2035, expanding at a CAGR of 7.9% from 2026 to 2035. The growing chronic disease burden globally is increasing the use of activated clotting time (ACT) testing solutions. Growing demand for point-of-care diagnostics, expanding healthcare, growing government initiatives, technological advancements, and the launch of new products are also enhancing the market growth.

Key Takeaways

• The activated clotting time testing market will likely exceed USD 561.08 million by 2026.
• Valuation is projected to hit USD 1112.29 million by 2035.
• Estimated to grow at a CAGR of 7.9% starting from 2026 to 2035.
• North America held the major revenue share of approximate 39% in the global activated clotting time testing market in 2025.
• Asia Pacific held approximately 22% share of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By product type, the consumables segment held a dominant revenue share of approximate 88% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By test type, the high-range ACT tests segment held a dominant revenue share of approximate 68% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By application type, the hemodialysis segment held a dominant revenue share of approximate 48% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of approximate 75% in 2025 and is expected to grow at the fastest CAGR during the forecast period.

What is Activated Clotting Time Testing?

The activated clotting time testing market is driven by growing incidences of cardiovascular diseases and increasing volume of complex surgical procedures. The activated clotting time testing refers to the diagnostic test developed for the measurement of blood clotting time. These tests are used for monitoring anticoagulation during various surgical procedures, detecting coagulation abnormalities, guiding heparin dosing, and preventing any complications.

What are the Applications of AI in the Market?

AI offers a wide range of applications in the activated clotting time testing market, such as real-time data analysis, providing rapid interpretations. They also help in autocalibration and adjustments of various parameters to enhance the test accuracy, where they also promote easy integration with healthcare systems for long-term tracking of cardiovascular status. They are also used for anticoagulant therapy adjustments and personalized heparin dosing, with reduced errors and complications.

Trends & Future Outlook of the Market

Growing Surgical and Dialysis Procedures

The growing cardiovascular and kidney diseases are increasing the demand for activated clotting time testing during their surgical procedures, angioplasty, and hemodialysis for real-time heparin and coagulation monitoring.

Expanding Point-of-Care Testing

A rise in bedside or rapid diagnostics is driving the adoption of activated clotting time testing solutions due to their accuracy and user-friendly approaches, as well as encouraging the development of portable and automated devices.

Blooming Technological Innovations

The growing technological advancements are propelling the development of new activated clotting time testing solutions with enhanced accuracy and clinical decisions, with reduced human errors by integrating digital health tools.

Key Indicators and Highlights

Segmental Insights

By Product Insights

The Consumables Segment Dominated the Market With an Approximate 88% in 2025

The consumables segment led the activated clotting time testing market with an approximate 88% share in 2025 and is expected to grow at the fastest CAGR during the predicted time, due to their single-time use, which increased their continuous demand across the healthcare sector. Each ACT test requires new reagents, activators, or cartridges, which increases their use. Additionally, growth in the testing volumes also increased their adoption rates.

The ACT analyzers segment held the second-largest share of approximate 12% of the market in 2025, driven by their high adoption for point-of-care testing. Their easy use and minimal errors are also increasing their demand. Additionally, the growing number of surgical procedures and personalized medicine demands are also increasing their use for real-time anticoagulation monitoring and precise heparin dosing.

By Test Type Insights

The High-Range ACT Tests Segment Dominated the Market With an Approximate 68% in 2025

The high-range ACT tests segment accounted for the highest revenue share of approximate 68% of the activated clotting time testing market in 2025 and is expected to show the highest CAGR growth during the predicted time, due to growth in the cardiac surgeons. They were used for high-dose heparin therapy and real-time coagulation monitoring. Moreover, their widespread availability also increased their adoption rates.

The low-range ACT tests segment held the second-largest share of approximate 32% of the market in 2025, due to a growing shift towards minimally invasive procedures. The growing adoption of precision medicines and increasing disease screening programs are also increasing their use. At the same time, technological advancements are also driving their innovations.

By Application Insights

The Hemodialysis Segment Dominated the Market with an Approximate 48% in 2025

The hemodialysis segment held a major revenue share of approximate 48% of the activated clotting time testing market in 2025 and is expected to expand rapidly with the fastest CAGR during the upcoming years, due to frequent anticoagulation requirements. Growth in patient volume and demand for point-of-care testing also increased their use. Their real-time and safe anticoagulation monitoring also increased their acceptance rates.

The cardiovascular surgery segment held the second-largest share of approximate 30% of the market in 2025, due to growing demand for high-dose heparin. The growing focus on patient safety and point-of-care testing solutions is also increasing the use of activated clotting time tests. Their rapid and accurate results and real-time monitoring are also increasing their adoption rates to tackle the growing surgical volume.

The interventional cardiology segment held approximate 22% of the activated clotting time testing market share in 2025, due to a growing shift toward minimally invasive procedures. This, in turn, is increasing the demand for activated clotting time testing solutions for procedures like angioplasty. The growing cardiovascular diseases and outpatient care options are also increasing their use, offering bedside monitoring, careful anticoagulation, and safe and precise heparin dosing.

By End-Use Insights

The Hospitals Segment Dominated the Market with an Approximate 75% in 2025

The hospitals segment contributed the biggest revenue share of approximate 75% of the activated clotting time testing market in 2025 and is expected to gain the highest CAGR share during the upcoming years, due to the presence of high patient volume, which increased the demand for anticoagulation monitoring. At the same time, growth in the surgical procedures also increased the use of activated clotting time tests. The presence of trained personnel, the availability of point-of-care devices, and regulatory compliance also increased their acceptance rates.

The diagnostic laboratories segment held the second-largest share of approximate 15% of the market in 2025, due to growing demand for outpatient testing, which is increasing the use of activated clotting time tests for preoperative and routine anticoagulant testing. Expanding laboratories and growing health awareness are also increasing their use for early disease detection. The growing cardiovascular and kidney diseases are also increasing their use, where their affordable solution are also attracting the patients.

The ambulatory surgical centers segment held approximate 10% of the activated clotting time testing market share in 2025, due to expanding outpatient procedures, where the growing minimally invasive surgeries are also increasing the demand for activated clotting time testing solutions. Growing demand for rapid anticoagulation monitoring and point-of-care testing is also increasing their use. Additionally, their cost-effective alternative and same-day surgeries are also increasing their acceptance rates.

Regional Insights

Advanced Healthcare Drives North America

North America dominated the activated clotting time testing market with approximate 39% in 2025, due to the presence of advanced healthcare infrastructure, which increased the adoption of activated clotting time testing solutions. The presence of strong companies and a high cardiovascular disease burden also increased their use. The growth in surgical procedures and high healthcare spending also increased their use, which contributed to the market growth.

U.S. Market Trends

The growing incidence of cardiovascular disease and the surgical procedures in the U.S. are driving the demand for activated clotting time testing solutions. The presence of advanced healthcare, medical device companies, and a robust R&D ecosystem is also increasing their use and innovations. Technological advancements and high healthcare spending are also driving their innovations.

Healthcare Expansion Boost Asia Pacific

Asia Pacific held approximately 22% share of the activated clotting time testing market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to rapid healthcare expansion and high patient population. Growing cardiovascular and kidney diseases are increasing the use of activated clotting time testing during their surgical procedures. Expanding point-of-care testing and government initiatives are also driving the market growth.

Japan Market Trends

The presence of advanced healthcare systems in Japan is increasing the use of activated clotting time testing to deal with the rising cardiovascular disease burden. The growing geriatric population and surgical volumes are also increasing their use. High healthcare expenditure, expanding medical device companies, and technological advancements are driving their innovations.

Europe Driven by Growing Cardiovascular Burden

Europe held approximately 26% share of the market in 2025 and is expected to grow significantly in the activated clotting time testing market during the forecast period, due to the growing cardiovascular burden and high geriatric population. This is increasing the adoption of activated clotting time testing across healthcare systems for surgical procedures. Growing technological advancements and expanding medical device companies are also increasing their innovations and use, promoting the market growth.

UK Market Trends

The UK consists of robust healthcare systems and medical device companies, which are driving the adoption and advancements of the activated clotting time testing solutions. The growing demand for anticoagulant monitoring and point-of-care testing is also increasing their adoption rates. Growing focus on patient safety and quality care is also increasing their use.

Market Value Chain Analysis

R&D

• The R&D of the activated clotting time testing focuses on enhancing point-of-care accuracy with the use of advanced optical detection, integrated hospital data systems, and AI-assisted analytics.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Clinical Trials and Regulatory Approvals

• The reproducibility, analytical precision, and clinical correlation are evaluated in the clinical trials and regulatory approvals of the activated clotting time testing.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Formulation and Final Dosage Preparation

• The formulation and final dosage preparation of activated clotting time testing involve lyophilized or liquid surface activators pre-measured into single-use plastic tubes or microfluidic cartridges.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Packaging and Serialization

• The packaging and serialization of activated clotting time testing involves the use of individually foil-wrapped, sterile cartridges or tubes, integrated barcodes, and lot-specific serialization.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Distribution to Hospitals, Pharmacies

• Global logistics networks and authorized medical distributors are responsible for the distribution of the activated clotting time testing to the hospitals and pharmacies.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Patient Support and Services

• The educational resources and 24/7 technical assistance are provided in the patient support and services of the activated clotting time testing.
• Key players: Abbott Laboratories, Werfen, Medtronic plc.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The activated clotting time testing offers rapid results, which increases its adoption for immediate clinical decisions.
• They offer a point-of-care testing approach and are easy to use, which increases their acceptance rates.
• They also provide whole blood tests and coagulation status, which promotes their adoption rates.
• They are also used for monitoring high-dose heparin therapy, driving their adoption during cardiac surgeries.

Weaknesses

• Lower sensitivity due to low heparin levels and other patient factors acts as the major weakness in the activated clotting time testing market, limiting its use.
• Poor standardization and limited accuracy also reduce their acceptance rates.

Opportunities

• The growing cardiovascular diseases are driving the demand for activated clotting time testing.
• Rapid expansion of point-of-care testing has also increased its adoption rates.
• Expanding cardiology and dialysis centres are also increasing their use.
• The growing technological advancements are also driving the development of new testing solutions.

Threats

• Stringent regulation and quality control slow down the advancement of the activated clotting time testing.
• Rapid technological advancements and high market competition also limit their innovations.

What are the Major Recent Developments in the Market?

• In February 2026, a new discovery was made by the University of Queensland by incorporating Rapid serum blood collection technology, that is Q-Sera of UQ start-up company, into a tube called VenoJect II RAPClot of Terumo Corporation, which utilized Australian snake venom's blood-clotting proteins and translated them into a pathology product.
• In February 2026, a technique for the detection of blood clot formation utilizing changes in reflected light on the surface of implants was patented by the researchers at IIT Madras, which helps in determining the viability of materials to be made into implants and testing water purity.

Segments Covered in the Report

By Product

• Consumables
• ACT Analyzers 

By Test Type

• High-Range ACT Tests 
• Low-Range ACT Tests 

By Application

• Hemodialysis
• Cardiovascular Surgery 
• Interventional Cardiology

By End-Use

• Hospitals
• Diagnostic Laboratories
• Ambulatory Surgical Centers

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA